GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dynavax Technologies Corp (NAS:DVAX) » Definitions » Cyclically Adjusted FCF per Share

Dynavax Technologies (Dynavax Technologies) Cyclically Adjusted FCF per Share : $-1.64 (As of Mar. 2024)


View and export this data going back to 2004. Start your Free Trial

What is Dynavax Technologies Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Dynavax Technologies's adjusted free cash flow per share for the three months ended in Mar. 2024 was $-0.134. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-1.64 for the trailing ten years ended in Mar. 2024.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 16.50% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 16.40% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 13.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Dynavax Technologies was 17.50% per year. The lowest was 4.50% per year. And the median was 13.50% per year.

As of today (2024-05-18), Dynavax Technologies's current stock price is $11.11. Dynavax Technologies's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was $-1.64. Dynavax Technologies's Cyclically Adjusted Price-to-FCF of today is .


Dynavax Technologies Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Dynavax Technologies's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dynavax Technologies Cyclically Adjusted FCF per Share Chart

Dynavax Technologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.43 -2.85 -2.31 -2.07 -1.66

Dynavax Technologies Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.95 -1.84 -1.74 -1.66 -1.64

Competitive Comparison of Dynavax Technologies's Cyclically Adjusted FCF per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Dynavax Technologies's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dynavax Technologies's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dynavax Technologies's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Dynavax Technologies's Cyclically Adjusted Price-to-FCF falls into.



Dynavax Technologies Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Dynavax Technologies's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.134/131.7762*131.7762
=-0.134

Current CPI (Mar. 2024) = 131.7762.

Dynavax Technologies Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -0.880 100.560 -1.153
201409 -0.889 100.428 -1.167
201412 -0.659 99.070 -0.877
201503 -0.915 99.621 -1.210
201506 -0.839 100.684 -1.098
201509 -0.700 100.392 -0.919
201512 -0.747 99.792 -0.986
201603 -0.773 100.470 -1.014
201606 -0.720 101.688 -0.933
201609 -0.774 101.861 -1.001
201612 -0.714 101.863 -0.924
201703 -0.609 102.862 -0.780
201706 -0.350 103.349 -0.446
201709 -0.299 104.136 -0.378
201712 -0.295 104.011 -0.374
201803 -0.652 105.290 -0.816
201806 -0.556 106.317 -0.689
201809 -0.584 106.507 -0.723
201812 -0.558 105.998 -0.694
201903 -0.796 107.251 -0.978
201906 -0.674 108.070 -0.822
201909 -0.415 108.329 -0.505
201912 -0.296 108.420 -0.360
202003 -0.423 108.902 -0.512
202006 -0.231 108.767 -0.280
202009 -0.251 109.815 -0.301
202012 -0.150 109.897 -0.180
202103 0.320 111.754 0.377
202106 0.923 114.631 1.061
202109 0.535 115.734 0.609
202112 0.623 117.630 0.698
202203 -0.347 121.301 -0.377
202206 0.092 125.017 0.097
202209 0.398 125.227 0.419
202212 0.220 125.222 0.232
202303 0.206 127.348 0.213
202306 0.179 128.729 0.183
202309 0.200 129.860 0.203
202312 0.093 129.419 0.095
202403 -0.134 131.776 -0.134

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Dynavax Technologies  (NAS:DVAX) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Dynavax Technologies Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Dynavax Technologies's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Dynavax Technologies (Dynavax Technologies) Business Description

Traded in Other Exchanges
Address
2100 Powell Street, Suite 900, Emeryville, CA, USA, 94608
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
Executives
Robert Janssen officer: Chief Medical Officer and VP C/O DYNAVAX TECHNOLOGIES, 2929 SEVENTH STREET, SUITE 100, BERKELEY CA 94710
David F Novack officer: Senior Vice President 39 YORKSHIRE DR, OAKLAND CA 94618
Hack Andrew A. F. director 300 THIRD STREET, FIRST FLOOR, CAMBRIDGE MA 02142
Justin Burgess officer: Principal Accounting Officer C/O DYNAVAX TECHNOLOGIES CORPORATION, 2100 POWELL STREET, SUITE 1900, EMERYVILLE CA 94608
Ryan Spencer officer: Co-President and Senior VP C/O DYNAVAX TECHNOLOGIES CORPORATION, 2929 SEVENTH STREET, SUITE 100, BERKELEY CA 94710-2753
Francis Cano director 11 ACORN LANE, LOS ALTOS CA 94022
Elaine D Sun director 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Scott Dunseth Myers director C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121
Kelly Macdonald officer: SVP and CFO 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Peter R. Paradiso director C/O DYNAVAX TECHNOLOGIES CORPORATION, 2100 POWELL STREET, SUITE 900, EMERYVILLE CA 94608
Julia Marie Eastland director C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121
Brent Macgregor director C/O DYNAVAX TECHNOLOGIES CORPORATION, 2100 POWELL STREET, SUITE 900, EMERYVILLE CA 94608
Peggy V Phillips director C/O DYNAVAX TECHNOLOGIES CORPORATION, 2929 SEVENTH STREET, SUITE 100, BERKELEY CA 94710
Robert Coffman officer: Chief Science Officer and VP C/O DYNAVAX TECHNOLOGIES CORP, 2929 SEVENTH ST STE 100, BERKELEY CA 94710
Michael S Ostrach officer: VP, CBO, and General Counsel 1300 SEAPORT BOULEVARD, REDWOOD CITY CA 94063